These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effective vaccine safety systems in all countries: a challenge for more equitable access to immunization. Amarasinghe A; Black S; Bonhoeffer J; Carvalho SM; Dodoo A; Eskola J; Larson H; Shin S; Olsson S; Balakrishnan MR; Bellah A; Lambach P; Maure C; Wood D; Zuber P; Akanmori B; Bravo P; Pombo M; Langar H; Pfeifer D; Guichard S; Diorditsa S; Hossain MS; Sato Y Vaccine; 2013 Apr; 31 Suppl 2():B108-14. PubMed ID: 23598471 [TBL] [Abstract][Full Text] [Related]
4. Capacity for a global vaccine safety system: the perspective of national regulatory authorities. Graham JE; Borda-Rodriguez A; Huzair F; Zinck E Vaccine; 2012 Jul; 30(33):4953-9. PubMed ID: 22658930 [TBL] [Abstract][Full Text] [Related]
5. Post-licensure rapid immunization safety monitoring program (PRISM) data characterization. Baker MA; Nguyen M; Cole DV; Lee GM; Lieu TA Vaccine; 2013 Dec; 31 Suppl 10():K98-112. PubMed ID: 24331080 [TBL] [Abstract][Full Text] [Related]
6. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Shimabukuro TT; Nguyen M; Martin D; DeStefano F Vaccine; 2015 Aug; 33(36):4398-405. PubMed ID: 26209838 [TBL] [Abstract][Full Text] [Related]
8. Landscape analysis of pharmacovigilance and related practices among 34 vaccine manufacturers' from emerging countries. Hartmann K; Pagliusi S; Precioso A Vaccine; 2020 Jul; 38(34):5490-5497. PubMed ID: 32591289 [TBL] [Abstract][Full Text] [Related]
9. Adverse events following immunization: is this time for the use of WHO causality assessment? Tafuri S; Gallone MS; Calabrese G; Germinario C Expert Rev Vaccines; 2015 May; 14(5):625-7. PubMed ID: 25805053 [TBL] [Abstract][Full Text] [Related]
10. Examining Socioeconomic and Computational Aspects of Vaccine Pharmacovigilance. Soldatou V; Soldatos A; Soldatos T Biomed Res Int; 2019; 2019():6576483. PubMed ID: 30911546 [TBL] [Abstract][Full Text] [Related]
12. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise. Nguyen M; Ball R; Midthun K; Lieu TA Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():291-7. PubMed ID: 22262619 [TBL] [Abstract][Full Text] [Related]
13. Smart Safety Surveillance (3S): Multi-Country Experience of Implementing the 3S Concepts and Principles. Iessa N; Macolic Sarinic V; Ghazaryan L; Romanova N; Alemu A; Rungapiromnan W; Jiamsuchon P; Pokhagul P; Castro JL; Macias Saint-Gerons D; Ghukasyan G; Teferi M; Gupta M; Pal SN Drug Saf; 2021 Oct; 44(10):1085-1098. PubMed ID: 34331675 [TBL] [Abstract][Full Text] [Related]
14. Reference set for performance testing of pediatric vaccine safety signal detection methods and systems. Brauchli Pernus Y; Nan C; Verstraeten T; Pedenko M; Osokogu OU; Weibel D; Sturkenboom M; Bonhoeffer J; Vaccine; 2016 Dec; 34(51):6626-6633. PubMed ID: 26496461 [TBL] [Abstract][Full Text] [Related]
16. Preface to supplement. Active surveillance of vaccine safety in the US Food and Drug Administration's Mini-Sentinel program: identification of exposures and outcomes. Vaccine; 2013 Dec; 31 Suppl 10():K1. PubMed ID: 24331068 [No Abstract] [Full Text] [Related]
17. The "Fluad Case" in Italy: Could it have been dealt differently? Levi M; Sinisgalli E; Lorini C; Santomauro F; Chellini M; Bonanni P Hum Vaccin Immunother; 2017 Feb; 13(2):379-384. PubMed ID: 27924687 [TBL] [Abstract][Full Text] [Related]
18. Perspectives on the future of postmarket vaccine safety surveillance and evaluation. Ball R Expert Rev Vaccines; 2014 Apr; 13(4):455-62. PubMed ID: 24606417 [TBL] [Abstract][Full Text] [Related]